This Article  • Full text  • PDF  • Reply to article  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Topic Collections  • Cataracts/ Lens  • Endophthalmitis  • Vitreoretinal Surgery  • Ophthalmological Procedures, Other  • Alert me on articles by topic

Harry W. Flynn Jr, MD; Ingrid U. Scott, MD, MPH

Arch Ophthalmol. 2008;126(4):559-561.

	Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings.

Endophthalmitis following cataract surgery is one of the most feared complications in ophthalmology. It has been estimated that approximately 1 case per 1000 cataract operations will be associated with this complication. Because there are more than 1.7 million cataract operations per year performed in the United States,¹ the magnitude of this problem is significant. Under the leadership of Bernard Doft, MD, and the National Eye Institute, the Endophthalmitis Vitrectomy Study (EVS) Group was organized in the late 1980s to undertake a prospective clinical trial (the EVS) evaluating the roles of pars plana vitrectomy and systemic antibiotics in the management of acute-onset endophthalmitis following cataract surgery or secondary intraocular lens implantation. ^2-3

Following the introduction of pars plana vitrectomy in 1970, the role of this treatment modality for endophthalmitis was controversial.⁴ The theoretical advantages of pars plana vitrectomy include débriding the intravitreal . . . [Full Text of this Article]

AUTHOR INFORMATION
Author Affiliations: Department of Ophthalmology, Bascom Palmer Eye Institute, University of Miami Miller School of Medicine, Miami, Florida (Dr Flynn); and Departments of Ophthalmology and Public Health Sciences, Penn State College of Medicine, Hershey, Pennsylvania (Dr Scott).